Correlation of Hepcidin with Hemoglobin and Iron Parameters in Iraqi Patients with Beta -Thalassemia major


  • sameh nahi The Ministry of Higher Education and Scientific Research
  • Ferdous Jabir



Beta thalassemia major, Hepcidin, Hemoglobin, Iron parameter


Background: Thalassemia is characterized by genetic abnormalities in the synthesis of hemoglobin, leading to a decrease or missing production of one or more in the globin chains. Consequently, this disrupts the synthesis of hemoglobin molecules, resulting in anemia, which is a prominent manifestation of thalassemia. Iron is an essential element for cellular health and is involved in various functions, including oxygen transportation, biomolecule synthesis, respiration, and homeostasis. Hepcidin, a low molecular weight peptide produced in the liver, plays a crucial role in regulating iron homeostasis. Objectives: Study the correlation of Hepcidin with Hemoglobin, Ferritin, and Iron Parameters in  Patients with Beta-Thalassemia major. Methods: The serum ferritin of all subjects was measured by the ELFA technique (Enzyme Linked Fluorescent Assay), Serum Hepcidin is measured by the ELISA kit, and Iron, UIBC as well as TIBC are measured via colorimetric methods. Results: The { mean ± SD } of Ages and Genders among Patients with healthy groups were not significant. The { mean ± SD } of Hb and serum levels of Iron, UIBC, TIBC, Hepcidin concentration, and BMI between  Patients and healthy groups were statistically significant. The study results of the correlation between Hepcidin and other markers in the beta-thalassemia patient's group showed a non-significant negative correlation of hepcidin with TIBC and UIBC. while there is a non-significant weak correlation between hepcidin with Hb and Ferritin. and the results have shown a non-significant positive correlation between hepcidin and Iron. Conclusion: In this study showed a marked reduction in hemoglobin production and high levels of Iron and Ferritin concentration, while the concentration of TIBC and UIBC was observed to decrease in individuals with this disease compared to healthy individuals. This study showed low hepcidin concentration in ?-TM major patients compared to healthy subjects.                          


Author Biography

Ferdous Jabir




Attina’ G, Triarico S, Romano A, Maurizi P, Mastrangelo S, Ruggiero A. Role of Partial Splenectomy in Hematologic Childhood Disorders. Pathogens. 2021;10(11):1436.

Hamdy M, Shaheen I, El-Gammal ZM, Ramadan YM. Detection of Renal Insufficiency in a Cohort of Patients With Beta-thalassemia Major Using Cystatin-C. J Pediatr Hematol Oncol. 2021;43(8):e1082–7.

Modell B, Darlison M. Global epidemiology of hemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480–7.

Harbi NS, Jawad AH, Alsalman FK. Evaluation of adipokines concentration in Iraqi patients with major and minor beta-thalassemia. Reports Biochem Mol Biol. 2020;9(2):209.

Giardine BM, Joly P, Pissard S, Wajcman H, K. Chui DH, Hardison RC, et al. Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2021;49(D1):D1192–6.

Wolff F, de Verneuil H, Rucheton B, Lefebvre T, Vialaret J, Ropert-Bouchet M, et al. Hepcidin: immunoanalytic characteristics. In: Annales de Biologie Clinique. 2018. p. 705–15.

Park CH, Valore E V, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–10.

Agarwal AK, Yee J. Hepcidin. Adv Chronic Kidney Dis. 2019;26(4):298–305.

Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacol Ther. 2015;146:35–52.

Azemin W-A, Alias N, Ali AM, Shamsir MS. Structural and functional characterisation of HepTH1-5 peptide as a potential hepcidin replacement. J Biomol Struct Dyn. 2021;1–24.

Pandya NK, Sharma S. Capnography and pulse oximetry. In: StatPearls [Internet]. StatPearls Publishing; 2021.

Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5(1):1–15.

Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics. 2021;11(17):8412.

Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int. 2017;21:S6–20.

Song Y, Yang N, Si H, Wang H, Liu T, Geng H, et al. Iron Overload Induces Vascular Calcification in Rat Aorta.

Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with ?-thalassemia. Expert Rev Hematol. 2020;13(1):85–94.

Lee HJ, Choi JS, Lee HJ, Kim W-H, Park SI, Song J. Effect of excess iron on oxidative stress and gluconeogenesis through hepcidin during mitochondrial dysfunction. J Nutr Biochem. 2015;26(12):1414–23.

Rija FF, Hussein SZ, Abdalla MA. Physiological and immunological disturbance in rheumatoid arthritis patients. Baghdad Sci J. 2021;18(2):247–52.

Bowen RAR, Remaley AT. Interferences from blood collection tube components on clinical chemistry assays. Biochem medica. 2014;24(1):31–44.

Bishop ML. Clinical Chemistry: Principles, Techniques, and Correlations, Enhanced Edition: Principles, Techniques, and Correlations. Jones & Bartlett Learning; 2020.

Schnedl WJ, Schenk M, Lackner S, Holasek SJ, Mangge H. ?-thalassemia minor, carbohydrate malabsorption and histamine intolerance. J Community Hosp Intern Med Perspect. 2017;7(4):227–9.

Ayukarningsih Y, Amalia J, Nurfarhah G. THALASSEMIA AND NUTRITIONAL STATUS IN CHILDREN. J Heal Dent Sci. 2022;2(1):39–52.

Al-Shemery MK, Al-Dujaili AN. Estimation of osteoprotgrin level in B thalassemia patient. In: AIP Conference proceedings. AIP Publishing LLC; 2019. p. 40011.

Shamoun M, Callaghan M. Thalassemia. In: Benign Hematologic Disorders in Children: A Clinical Guide. Springer; 2020. p. 91–8.

Haley K. Congenital hemolytic anemia. Med Clin. 2017;101(2):361–74.

Reinish AL, Noronha SA. Anemia at the Extremes of Life: Congenital Hemolytic Anemia. Anemia Young Old Diagnosis Manag. 2019;95–135.

Hajimoradi M, Haseli S, Abadi A, Chalian M. Musculoskeletal imaging manifestations of beta-thalassemia. Skeletal Radiol. 2021;50(9):1749–62.

Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T. Iron metabolism: Pathophysiology and pharmacology. Trends Pharmacol Sci. 2021;42(8):640–56.

Mustafa BS. Defining Pathological Iron Status in Children with Thalassemia. Iraqi J Pharm. 2022;19(2):108–16.

Ficiarà E, Munir Z, Boschi S, Caligiuri ME, Guiot C. Alteration of iron concentration in Alzheimer’s disease as a possible diagnostic biomarker unveiling ferroptosis. Int J Mol Sci. 2021;22(9):4479.

Menaka Devi M. Prevalence of Beta Thalassemia Trait among Antenatal Women Attending a Tertiary Care Centre. Stanley Medical College, Chennai; 2020.

Abbass SAR, Defer IH. Some biochemical parameters in Iraqi patients with thalassemia and related with DM1. Int J Chem. 2011;1(5):46–56.

Quiles del Rey M, Mancias JD. NCOA4-mediated ferritinophagy: a potential link to neurodegeneration. Front Neurosci. 2019;13:238.

Cleland SR, Thomas W. Iron homeostasis and perioperative management of iron deficiency. BJA Educ. 2019;19(12):390.

Manara R, Ponticorvo S, Tartaglione I, Femina G, Elefante A, Russo C, et al. Brain iron content in systemic iron overload: A beta-thalassemia quantitative MRI study. NeuroImage Clin. 2019;24:102058.

Majhi SC, Mishra NR, Panda PC, Biswal SS. Serum ferritin as a diagnostic marker for cardiac iron overload among beta-thalassemia major children. Indian J Child Health. 2019;269–72.

Leecharoenkiat K, Lithanatudom P, Sornjai W, Smith DR. Iron dysregulation in beta-thalassemia. Asian Pac J Trop Med. 2016;9(11):1035–43.

Kowdley K V, Gochanour EM, Sundaram V, Shah RA, Handa P. Hepcidin signaling in health and disease: ironing out the details. Hepatol Commun. 2021;5(5):723–35.

Silvestri L, Nai A, Dulja A, Pagani A. Hepcidin and the BMP-SMAD pathway: An unexpected liaison. Vitam Horm. 2019;110:71–99.

Xiao X, Alfaro-Magallanes VM, Babitt JL. Bone morphogenic proteins in iron homeostasis. Bone. 2020;138:115495.

Prathyusha K, Venkataswamy M, Goud KS, Ramanjaneyulu K, Himabindu J, Raj KS. Thalassemia-A Blood Disorder, its Cause, Prevention and Management. Res J Pharm Dos Forms Technol. 2019;11(3):186–90.

De Sanctis V, Soliman AT, Tzoulis P, Daar S, Fiscina B, Kattamis C. Pancreatic changes affecting glucose homeostasis in transfusion dependent ?-thalassemia (TDT): A short review. Acta Bio Medica Atenei Parm. 2021;92(3).

Vogt A-CS, Arsiwala T, Mohsen M, Vogel M, Manolova V, Bachmann MF. On iron metabolism and its regulation. Int J Mol Sci. 2021;22(9):4591.

Lal A. Iron in health and disease: An update. Indian J Pediatr. 2020;87(1):58–65.

Ma W, Jia L, Xiong Q, Feng Y, Du H. The role of iron homeostasis in adipocyte metabolism. Food Funct. 2021;12(10):4246–53.

Tantiworawit A, Khemakapasiddhi S, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, et al. Correlation of hepcidin and serum ferritin levels in thalassemia patients at Chiang Mai University Hospital. Biosci Rep. 2021 Feb 1;41(2).

Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation driven pathophysiology of iron homeostasis—mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732.

Winn NC, Volk KM, Hasty AH. Regulation of tissue iron homeostasis: the macrophage “ferrostat.” JCI insight. 2020;5(2).